RE:COOL they answer my question ... 28 weeks to the end of Part1 from a start in early March takes us to mid/late Aug to get to the end of dose escalation with ~25 patients enrolled. We are pretty much half way now, maybe just entering the possible therapeutic dose level +/- a few weeks.
I think they have a good rationale for taking all-comers, interesting to hear that's driven by what the FDA want. As I said they want to data to guide them on the efficacy/sortilin expression relationship, not prescribe that with assumptions.
stephanedodier wrote: About FDA Phase 2 timeframe. They dont take just analyst questions....